The aim of this study was to investigate the serum levels of VICM in biologic disease-modifying anti-rheumatic drugs (bDMARDs)-naïve patients with RA and healthy donors, and to compare VICM to the levels of the non-citrullinated MMP-derived fragments of vimentin (VIM) and anti-CCP. This evidence concerns the gene VIM and rheumatoid arthritis.